Influence of hemodialysis on incretin hormones and insulin secretion in diabetic and non-diabetic patients

International Urology and Nephrology

Volumn 45, Issue 6, 2013, Pages 1733-1740

  Masajtis Zagajewska, Anna ^a   Kurnatowska, Ilona ^a   Wajdlich, Małgorzata ^a   Jagodzińska, Marta ^a   Nowicki, Michał ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Hemodialysis; Incretin hormones; Insulin secretion

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; FEMALE; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FASTING; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS;

EID: 84890792601     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-013-0457-4     Document Type: Article

References (40)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like-peptide- 17-36: a physiological incretin in man. Lancet 2:1300-1304
2. Creutzfeld W (1979) The incretin concept today. Diabetologia 16:75-85
3. Creutzfeld W, Nauck M (1992) Gut hormones and diabetes mellitus. Diabetes Metab Rev 8:149-177
4. Nauck MA, Homberger E, Siegel EG et al (1986) Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 6:492-498
5. Nauck MA, Stockmann F, Ebert R, Creutzfeld W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52
6. Brown JC, Mutt V, Pederson RA (1970) Further purification of polypeptide demonstrating enterogastrone activity. J Physiol 209:57-64
7. Schmidt WE, Siegel EF, Creutzfeldt W (1985) Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28:704-707
8. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439
9. Deacon CF (2004) Therapeutic strategies based on glucagon peptide like 1. Diabetes 53:2181-2189
10. Holst JJ (1996) Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signaling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 271:E458-E464
11. Ritz E, Orth SR (1999) Nephropathy in patients with type 2 diabetes mellitus. N Engel J Med 50:609-613
12. Ruiz Grande C, Pintado J, Alarcon C, Castilla C, Valverde I, Lopez Novoa JM (1990) Renal catabolism of human glucagon-like peptides 1 and 2. Can J Physiol Pharmacol 68:1568-1573
13. Ruiz-Grande C, Alarcon C, Castila C, Lopez Novoa JM, Villanueva- Penacarrillo ML, Valverde I (1993) Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res 25:612-616
14. Sirinek KR, O'Dorisio TM, Gaskill HV, Levine BA (1984) Chronic renal failure effect of hemodialysis on gastrointestinal hormones. Am J Surg 148:732-775
15. Orskov C, Andreasen J, Holst JJ (1992) All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab 74:379-384
16. Yamaoka-Tojo M, Tojo T, Takahira N et al (2010) Elevated circulating levels o fan incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol 9:17
17. National Kidney Foundation KDOQI (2007) Clinical Practice Guidelines and Clinical Practice Recommendations for diabetes and chronic kidney disease. AJKD 2:S1-S180
18. Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
19. Orskov C, Welergren A, Holst JJ (1993) Biological effects and metabolic rate of glucagon-like peptide 1 (7-36) amide and glucagon-like peptide 1 (7-37) in healthy subjects are indistinguishable. Diabetes 42:658-661
20. Qualmann C, Nauck MA, Holst JJ, Orsocov C, Creutzfeld W (1995) Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 32:13-16
21. Holst JJ, Gromada J (2004) Role of incretin hormones in the regulation of insulin secretion in diabetic and non-diabetic humans. Am J Physiol Endocrinol Metab 287:E199-E206
22. Elahi D, McAloon-Dyke M, Fukagawa NK et al (1994) the insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51:63-74
23. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeld W (1993) Preserved incretin activity of glucagon-like peptide-1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Investig 91:301-307
24. Nauck MA, Kleine N, Orskov C, Holst JJ, Willys B, Creutzfeldt W (1993) Normalization of fasting hyperglycemia by exogenous glucagon-like peptide-1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744
25. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DMl (2005) Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54:146-151
26. Deacon C, Danielsen P, Klarskov L, Olesen M, Holst JJ (2001) Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic effects in anesthetized pigs. Diabetes 50:1588-1597
27. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ (1996) Glucagon-like-peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol Endocrinol Metab 251:E458-E464
28. Owyang C, Miller LJ, DiMango EP, Brennan LA, Go VLW (1979) Gastrointestinal hormone profile in renal insufficient. Mayo Clin Proc 54:769-773
29. Kenneth R, Thomas M, Haroid V, Barry A (1984) Chronic renal failure: effect of hemodialysis on gastrointestinal hormones. Am J Surg 148:732-736
30. Fernandez-Reyes MJ, Sanchez R, Garcia M, et al. (2010) Acute responses of gastrointestinal hormones to both oral and parenteral intradialytic nutrition. Am J Nephrol 32:272-278
31. Jones IR, Owens DR, Luzio S, Hayes TM (1989) Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the casting state in type 2 (non-insulin dependent) diabetes mellitus. Horm Metab Res 21:23-26
32. Nauck M, Stockmann F, Ebert R, Creutzfeld W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-54
33. Jones IR, Owens DR, Moody AJ, Luzio SD, Morris T, Hayes TM (1987) The effects of glucose-dependent insulinotropic polypeptide infused At physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 30:707-712
34. Gault VA, Parker JC, Harriott P, Flatt PR, O'Harte FP (2002) Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP (3-42), is a GIP receptor antagonist in vivo. J Endocrinol 175:525-533
35. U.K. Prospective Diabetes Study Group (1995) U.K. Prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258
36. Holman RR (1998) Assessing the potential for α-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Prac 40:S21-S25
37. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495
38. McAuley KA, Mann JT, Chase JG, Lotz TF, Shaw GM (2007) Point: HOMA: satisfactory for the time being. Diabetes Care 30:2411-2413
39. Hockaday D, Sayyad M, Yajnik C (2007) Counterpoint: appreciating homeostasis model assessment. Diabetes Care 30:2414-2418
40. Boyko EJ, Jensen CC (2007) Do we know what homeostasis model assessment measures? Diabetes Care 30:2725-2728